H. Lundbeck A/S: PharmaVitae Profile

This analysis examines the historical and forecast performance for Lundbeck in the prescription pharma global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Studien Infos ausblenden]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Lundbeck: PharmaVitae forecasts at a glance 7
Strategic insight 8
SWOT analysis 12
Strengths 12
Strong and improving financial position and ownership structure 12
Reputation as CNS market leader 13
Weaknesses 13
Patent expiry of Lexapro and, in 2014, Cipralex 13
Opportunities 13
Use cash reserves to pursue licensing and product acquisition deals 13
Continued US expansion 13
Threats 14
Failure of Lu AA21004 to demonstrate sufficient benefits to drive use over existing products 14
CHAPTER 3 QUARTERLY NEWS UPDATE 16
Product developments 16
Deals and alliances 17
Product deals 17
Technology deals 18
M&A activity 18
Company announcements 19
Future product milestones 19
CHAPTER 4 COMPANY INTRODUCTION 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 21
Current corporate structure 22
CHAPTER 5 COMPANY SALES 23
Key findings 23
Prescription pharmaceutical sales and growth rate analysis, 2001-13 24
Product analysis 26
Product analysis, 2001-07 26
Product analysis, 2007-13 28
Therapy area analysis 30
Therapy area analysis, 2001-07 31
Therapy area analysis, 2007-13 32
Therapy area focus, 2001-13 33
Geographic analysis 34
Geographic analysis, 2001-07 35
Geographic analysis, 2007-13 36
Geographic focus, 2001-13 38
Launch/core/expiry analysis 39
Explanation of launch/core/expiry analysis 39
Launch analysis, 2007-13 40
Core analysis, 2007-13 41
Expiry analysis, 2007-13 42
Launch/core/expiry configuration, 2007-13 43
Molecule type analysis 44
Molecule type analysis, 2001-07 45
Molecule type analysis, 2007-13 46
Externalization analysis 49
Externalization analysis, 2001-07 50
Externalization analysis, 2007-13 51
CHAPTER 6 COMPANY FINANCIALS 53
Key findings 53
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 54
Financial statements, 2001-07 55
Profit and loss account, 2001-07 55
Balance sheet, 2001-07 57
Operating costs and profit analysis 59
Operating costs and profit analysis, 2001-07 60
Operating cost ratio and profit margin analysis, 2001-07 61
Operating cost ratio and profit margin analysis, 2007-13 62
Operating costs and profit analysis, 2007-13 64
Return on capital employed analysis 65
Capital employed analysis, 2001-07 66
Return on capital employed analysis, 2001-07 68
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 71
Key findings 71
Overview 72
Central nervous system 73
Cipralex (including Lexapro royalties) 73
Overview 73
Sales forecast 74
Ebixa 78
Overview 78
Sales forecast 79
Lu AA21004 81
Overview 81
Sales forecast 82
CHAPTER 8 APPENDIX 85
R&D pipeline 85
References 85
Abbreviations 85
Exchange rates 86
[Inhaltsverzeichnis ausblenden]

Table 1: Lundbeck - PharmaVitae forecasts at a glance 7
Table 2: Lundbeck key product developments, Q1-Q3 2008 16
Table 3: Lundbeck product deals and alliances, Q1-Q3 2008 17
Table 4: Lundbeck technology deals and alliances, Q1-Q3 2008 18
Table 5: Lundbeck M&A activity, Q1-Q3 2008 18
Table 6: Lundbeck company announcements, Q1-Q3 2008 19
Table 7: Lundbeck future product milestones, 2008-10 19
Table 8: Lundbeck product portfolio overview ($m), 2001-07 26
Table 9: Lundbeck product portfolio overview ($m), 2007-13 28
Table 10: Lundbeck product portfolio overview ($m), 2001-07 31
Table 11: Lundbeck product portfolio overview ($m), 2007-13 32
Table 12: Lundbeck portfolio overview by geographic region ($m), 2001-07 35
Table 13: Lundbeck portfolio overview by geographic region ($m), 2007-13 36
Table 14: Lundbeck launch portfolio overview ($m), 2007-13 40
Table 15: Lundbeck core portfolio overview ($m), 2007-13 41
Table 16: Lundbeck expiry portfolio overview ($m), 2007-13 42
Table 17: Lundbeck portfolio overview by molecule type ($m), 2001-07 45
Table 18: Lundbeck product portfolio by molecule type ($m), 2007-13 46
Table 19: Lundbeck product portfolio overview by molecule type ($m), 2007-13 47
Table 20: Lundbeck product portfolio overview by source ($m), 2001-07 50
Table 21: Lundbeck product portfolio overview by source ($m), 2007-13 51
Table 22: Total Lundbeck sales by business unit ($m), 2001-07 54
Table 23: Lundbeck profit and loss account ($m), 2001-07 55
Table 24: Lundbeck balance sheet ($m), 2001-07 57
Table 25: Lundbeck operating revenue/cost analysis ($m), 2001-07 60
Table 26: Lundbeck operating cost ratio analysis (% of total revenues), 2001-07 61
Table 27: Lundbeck operating cost ratio analysis (% of total revenues), 2007-13 62
Table 28: Lundbeck operating revenue/cost analysis ($m), 2007-13 64
Table 29: Lundbeck capital employed ($m), 2001-07 66
Table 30: Lundbeck EBIT return on capital employed ($m), 2001-07 68
Table 31: Lundbeck EBIT pre-tax return/capital employed driver analysis (%), 2001-07 69
Table 32: Key products overview 72
Table 33: Cipralex: overview 73
Table 34: Cipralex: sales forecast ($m), 2007-13 74
Table 35: Lexapro royalties: sales forecast ($m), 2007-13 74
Table 36: Ebixa: overview 78
Table 37: Ebixa: sales forecast ($m), 2007-13 79
Table 38: Lu AA21004: overview 81
Table 39: Lu AA21004: sales forecast ($m), 2007-13 82
Table 40: Lundbeck's R&D pipeline (Phase I-registration) 85
Table 41: Exchange rates, 2007 86
Figure 1: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Lundbeck's financial performance ($m), 2001-13 6
Figure 3: CNS sales ($ billion), 2007 8
Figure 4: CNS sales ($ billion), 2013 9
Figure 5: CNS sales CAGR (%), 2007-13 10
Figure 6: CNS sector, launch/core/expiry analysis ($ billion), 2007-13 11
Figure 7: Lundbeck SWOT analysis 12
Figure 8: Current corporate structure 22
Figure 9: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 24
Figure 10: Lundbeck key sales growth driver and resistors ($m), 2001-07 27
Figure 11: Lundbeck key sales growth drivers and resistors ($m), 2007-13 29
Figure 12: Lundbeck prescription pharmaceutical sales by therapy area ($m), 2001-13 30
Figure 13: Lundbeck prescription pharma sales by therapy area (% of total), 2001-13 33
Figure 14: Lundbeck prescription pharmaceutical sales by geographic region ($m), 2001-13 34
Figure 15: Lundbeck growth drivers and resistors by geographic region ($m), 2001-07 35
Figure 16: Lundbeck drivers and resistors by geographic region ($m), 2007-13 37
Figure 17: Lundbeck prescription pharmaceutical sales by geographic region (% of total), 2001-13 38
Figure 18: Lundbeck launch/core/expiry configuration ($m), 2007-13 43
Figure 19: Lundbeck prescription pharmaceutical sales by molecule type ($m), 2001-13 44
Figure 20: Lundbeck growth drivers and resistors by molecule type ($m), 2007-13 48
Figure 21: Lundbeck prescription pharmaceutical sales by source ($m), 2001-13 49
Figure 22: Lundbeck growth drivers and resistors by source ($m), 2001-07 50
Figure 23: Lundbeck growth drivers and resistors by source ($m), 2007-13 52
Figure 24: Lundbeck operating revenue/cost analysis ($m), 2001-13 59
Figure 25: Lundbeck operating cost ratio analysis (% of total revenues), 2001-13 63
Figure 26: Lundbeck return on capital employed, EBIT margin and capital turnover, 2001-07 65
Figure 27: Return on capital employed formula 69
Figure 28: Lundbeck's Cipramil/Cipralex switch (% total), 2001-07 76
Figure 29: Forest's Celexa/Lexapro switch (% total), 2001-07 76
[Tabellenverzeichnis ausblenden]